Business
Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, announced today that the company will be hosting in-person one-on-one meetings coinciding with the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, January 12-15, 2026.
About this update from Achieve Life Sciences, Inc.
[{"type":"text","content":"SEATTLE and VANCOUVER, BC, Dec. 17, 2025 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, announced today that the company will be hosting in-person one-on-one meetings coinciding with the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, January 12-15, 2026.","length":443,"tagName":"p"},{"type":"text","content":"Rick Stewart, Chief Executive Officer of Achieve Life Sciences, along with other members of senior management, will provide an overview of Achieve's late-stage cytisinicline program for smoking and vaping cessation and discuss plans for the upcoming year.","length":259,"tagName":"p"},{"type":"text","content":"To schedule a one-on-one meeting with the company, please contact Investor Relations at [email protected].","length":115,"tagName":"p"},{"type":"image","alt":"Achieve Life Sciences Logo","displaySize":"","headline":null,"caption":"Achieve Life Sciences Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":209,"url":"https://media.zenfs.com/en/prnewswire.com/0a027b342740e9def531597adad688ba"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WRBDTOFbZl3Y.UGWmQ5Fng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM2ODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/0a027b342740e9def531597adad688ba","width":400,"height":209}},"href":"https://mma.prnewswire.com/media/2848157/Achieve_Life_Sciences_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"About Achieve Life Sciences, Inc. Achieve Life Sciences is a late-stage specialty pharmaceutical company committed to addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. In September 2025, the company announced that its New Drug Application, submitted to the U.S. Food and Drug Administration (FDA) in June 2025, had been accepted for review. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of June 20, 2026. The NDA is for cytisinicline to be used as a treatment of nicotine dependence for smoking cessation in adults, based on two successfully completed Phase 3 studies and its open-label safety study. Additionally, the company has ...